title: Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma.
abstract: Glucose uptake and glycolytic metabolism are enhanced in cancer cells compared to normal cells and tissues. Increased expression of glucose transporter 1 (GLUT1) has been reported in human malignant cells. The aim of this study is to determine the expression of the facilitative glucose transporter protein GLUT1 in human breast carcinomas and a possible correlation between GLUT1 expression and clinical outcome including disease-free or overall survival. One hundred consecutive formalin-fixed, paraffin-embedded sections of invasive breast carcinomas were evaluated by means of immunohistochemical staining of GLUT1. Forty-seven (47%) of 100 breast carcinomas showed positive staining for GLUT1. Expression of GLUT1 correlated significantly with nuclear grade (P < 0.001), estrogen receptor status (P = 0.002), and progesterone receptor status (P = 0.001). The mean disease-free survival periods of GLUT1-positive and -negative patients were 47 +/- 2.4 months and 54.3 +/- 1.3 months, respectively (P = 0.017). The mean overall survival periods of GLUT1-positive and -negative patients were 48.7 +/- 2.2 and 56.1+/- 1.3 months, respectively (P = 0.043). In the multivariate analysis, disease-free survival correlated significantly with GLUT1, tumor size, and lymph node involvement (P = 0.043, P = 0.014, and P = 0.045, respectively). In analysis of overall survival, however, lymph node involvement, tumor size, and nuclear grade were statistically significant (P = 0.024, P = 0.023, and P = 0.003, respectively). Our data suggest that absence of GLUT1 expression significantly increases disease-free survival. These findings demonstrate that GLUT1 expression in breast carcinoma can be a marker of aggressive biological behavior and identifies a worse prognosis in breast carcinoma patients.
authors.affiliation: Department of Surgery, Samsung Cheil Hospital & Women's Healthcare Center, Sungkyunkwan University School of Medicine, 1-19, Mookjung-Dong, Chung-Ku, Seoul, Korea, 100-380.
authors.forename: Sung Soo
authors.initials: SS
authors.lastname: Kang
authors.forename: Yi Kyeong
authors.initials: YK
authors.lastname: Chun
authors.forename: Min Hee
authors.initials: MH
authors.lastname: Hur
authors.forename: Hae Kyung
authors.initials: HK
authors.lastname: Lee
authors.forename: Yee Jeong
authors.initials: YJ
authors.lastname: Kim
authors.forename: Sung Ran
authors.initials: SR
authors.lastname: Hong
authors.forename: Jee Hyun
authors.initials: JH
authors.lastname: Lee
authors.forename: Sung Gong
authors.initials: SG
authors.lastname: Lee
authors.forename: Yong Koo
authors.initials: YK
authors.lastname: Park
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D005260:Female; D051272:Glucose Transporter Type 1; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009004:Monosaccharide Transport Proteins / Q000032:analysis*; D011379:Prognosis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate
chemical_list: D051272:Glucose Transporter Type 1; D009004:Monosaccharide Transport Proteins; D011980:Receptors, Progesterone; C495677:SLC2A1 protein, human